FLY-GEN is a spin-off startup aiming to deliver a new solution of natural active compounds, drug discovery, protein design and analytical research of natural products in regenerating medicine. It was cofounded by four specialists of the Biotech area, dr. Tomasz Skalski, CEO, cofounder dr. Artur Góra COO, cofounder, dr. Anna Kasprzycka CTO, cofounder and Tomasz Magdziarz, cofounder. We focus on scientific software development, in silico modelling, and applied engineering of antibacterial peptides as well as recombinant enzymes strictly targeting dead tissues of non-healing wounds.
FLY-GEN is committed to improve the lives of elder patients suffering from wounds problems. The Company uses the natural biological compounds, fixed into the neutral matrix, modified enzymatic proteins focused on direct effect on non-viable tissues. They prevents effectively against antibiotic resistant bacteria, pathogenic fungi as well as regulate or eliminate the wound bed biofilm.
FLY-GEN impacts the following areas:
- Provides methods for drug design and protein optimization
- Delivering new bioactive compounds and their composition with the neutral and biodegradable matrix
- Application driven protein re-engineering
- Efficient debridement and heeling of the wounds
- Decreasing the impact of diseases
- Making solutions based on microorganisms resistance
The biotechnology startup derives its name from the word, fly: a complex of medicinal maggots characterized by healing properties of the patient wounds and genes checking the genetic properties and its variation allowing to successfully fight with resistance of wound bacterial and fungal pathogens.
Our motto is: Understanding the natural biological processes, create the best efficient drugs.